6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cyclophotocoagulation in Neovascular Glaucoma with Near-Total Synechial Angle Closure

      case-report
      , ,
      Case Reports in Ophthalmological Medicine
      Hindawi

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To describe a single surgeon's experience utilizing prompt primary slow-burn transscleral cyclophotocoagulation (CPC) with prior or concurrent anti-VEGF and subsequent aqueous shunt as needed in NVG eyes with near-total synechial angle closure at presentation.

          Methods

          Retrospective chart review of all NVG patients with uncontrolled IOP, active anterior segment NV, near-total synechial angle closure, and no contraindications to prompt anti-VEGF who received CPC within 3 days of presentation with at least 6 months of follow-up.

          Results

          Eight patients with mean age 60.6 years were included. Underlying etiologies were CRVO ( N = 3), PDR ( N = 2), CRAO ( N = 1), BRVO ( N = 1), and chronic RD ( N = 1). All eyes underwent CPC with intravitreal anti-VEGF within 3 days of presentation. Five patients did not require subsequent aqueous shunts through a mean follow-up of 15 months; most recent visual acuities ranged from 20/40 to LP, and IOPs ranged from 5 to 11 mmHg on 0 to 3 IOP-lowering medications. Three patients who required subsequent tubes had complete regression of active anterior segment NV at the time of surgery. Most recent visual acuities ranged from 20/100 to 20/125, and IOPs ranged from 8 to 14 mmHg on 0 meds at a mean follow-up of 10 months. No eyes developed uncontrolled inflammation, sympathetic ophthalmia, or phthisis.

          Conclusion

          Prompt primary slow-burn CPC with prior or concurrent anti-VEGF may be an effective strategy to immediately lower IOP in acute NVG eyes with active anterior segment NV and near-total synechial angle closure. If IOP becomes uncontrolled later, an aqueous shunt can be implanted in a controlled setting after active anterior segment NV has regressed.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

          To evaluate the biologic efficacy of intravitreal bevacizumab (IVB) for iris neovascularization (INV) or neovascular glaucoma (NVG) in patients with ischemic retinal disorders. Retrospective, consecutive, interventional case series. Thirty patients (41 eyes) with INV or NVG secondary to ischemic retinal disorders. Patients received IVB (1 mg) as the initial treatment for INV or NVG and were followed up for at least 6 months. Ophthalmic evaluations included measurement of visual acuity and intraocular pressure (IOP), a complete ophthalmic examination, and fluorescein angiography. Patients were divided into 3 subgroups: INV without elevated IOP (INV group), NVG with an open angle (O-NVG group), and NVG with angle closure (C-NVG group) for outcomes analysis. The controllability of IOP by IVB, incidence of recurrence, and requirement for surgery to treat NVG. No significant ocular or systemic adverse events developed during follow-up (range, 6-22 months; mean, 13.3 months). The mean IOP levels were 14.7, 31.2, and 44.9 mmHg at baseline in the INV, O-NVG, and C-NVG groups, respectively. In the INV group (9 eyes), the INV regressed or resolved after 1 injection. Iris neovascularization recurred in 4 eyes by 6 months and stabilized after repeated injections without IOP elevation. In the O-NVG group (17 eyes), rapid neovascular regression with successful IOP normalization (
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study.

            The long-term efficacy and safety of filtering surgery with 5-fluorouracil (5-FU) in eyes with neovascular glaucoma are unknown.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              NEOVASCULAR SECONDARY GLAUCOMA, ETIOLOGY AND PATHOGENESIS.

              Neovascular secondary glaucoma is a condition characterized by increased intraocular pressure due to the neovascularization occurring at the iridocorneal angle and iris, the most common complication of end-stage ischemic retina. The early diagnosis and treatment of this disease are important, because the functional prognosis is reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Case Rep Ophthalmol Med
                Case Rep Ophthalmol Med
                CRIOPM
                Case Reports in Ophthalmological Medicine
                Hindawi
                2090-6722
                2090-6730
                2023
                26 October 2023
                : 2023
                : 5719002
                Affiliations
                Department of Ophthalmology & Visual Science, University of Chicago, Chicago, IL, USA
                Author notes

                Academic Editor: Maurizio Battaglia Parodi

                Author information
                https://orcid.org/0000-0002-0062-7386
                Article
                10.1155/2023/5719002
                10622186
                e23f4731-b216-41af-b8ec-49f341625f1c
                Copyright © 2023 Jessie Wang et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 4 January 2023
                : 16 September 2023
                : 7 October 2023
                Funding
                Funded by: Bucksbaum Institute for Clinical Excellence
                Categories
                Case Series

                Ophthalmology & Optometry
                Ophthalmology & Optometry

                Comments

                Comment on this article